Diligence memo · auto-generated · as of July 2, 2026
Chimerix Inc
Chimerix Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Chimerix Inc operates in Pharmaceuticals, based in DURHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Chimerix Inc has raised $96M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $45M on 2011-02-07.
Most recent recorded round closed around 2019-07-26.
Valuation (modeled)modeled
Provath models Chimerix Inc at approximately $1.2B (range $113M–$3.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.74× the median modeled value of Series C Pharmaceuticals companies in 2019–2021 (33 peers) — value vs value, same stage and era. Within the normal band (74% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 60 months.
Last raise 6.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 90% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Verastem, Inc., Sentia Wellness, Inc., Oyster Point Pharma, Inc., Terns Pharmaceuticals, Inc., Theseus Pharmaceuticals, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.